仑伐替尼在肝细胞癌中的耐药机制和对策研究进展  

Resistance of Lenvatinib and Its Use in the Treatment of Hepatocellular Carcinoma:a Review

作　　者：徐永康 吴建兵[1] XU Yong-kang;WU Jian-bing(Department of Oncology,the Second Affiliated Hospital of Nanchang University,Nanchang 330006,China)

机构地区：[1]南昌大学第二附属医院肿瘤科,南昌330006

出　　处：《南昌大学学报（医学版）》2024年第2期81-87,共7页Journal of Nanchang University：Medical Sciences

基　　金：国家自然科学基金项目(82060435)。

摘　　要：仑伐替尼是晚期肝癌有效的一线治疗药物。然而,许多患者在仑伐替尼治疗后出现疾病进展,耐药问题在治疗实践中普遍存在,临床急需逆转耐药策略。众多研究表明表观遗传学、细胞转运过程、肿瘤微环境、肿瘤干性以及细胞自噬、铁死亡等与仑伐替尼的耐药机制密切相关。文章对肝癌仑伐替尼耐药的机制研究进展进行归纳,并初步探讨耐药后临床治疗策略,旨在为改善仑伐替尼耐药患者预后提供理论基础。Lenvatinib is an effective first-line therapeutic agent for advanced hepatocellular carcinoma.However,many patients experience disease progression after lenvatinib treatment,and the problem of drug resistance is prevalent in therapeutic practice,urgently requiring strategies to reverse drug resistance.Numerous studies have shown that epigenetics,cell transport processes,tumor microenvironment,tumor dryness,as well as autophagy and ferroptosis,are closely related to the resistance mechanism of lenvatinib.This article summarizes the research progress on the mechanism of lenvatinib resistance in hepatocellular carcinoma,and preliminarily explores clinical treatment strategies to provide a theoretical basis for improving the prognosis of lenvatinib-resistant patients.

关 键 词：肝细胞癌 仑伐替尼 耐药性 临床策略 

分 类 号：R735.7[医药卫生—肿瘤]